📇 Rhumatologue · ELBEUF CEDEX · (76) · Salarié
Chargement de la fiche…
Chargement de la fiche…
MonRhumato.fr utilise des cookies pour mesurer l'audience (statistiques) et améliorer le site. Aucune donnée de santé identifiable n'est jamais collectée. Politique de confidentialité.
Votre choix est conservé 13 mois (durée max CNIL). Vous pouvez le modifier à tout moment via Préférences cookies.
2 raisons identifiées
Praticien-chercheur
10 articles scientifiques publiés — formation continue solide
Délais de RDV courts dans la région
119.2 rhumatos / 100 000 hab. — département bien doté
✨ Génération du profil synthétique IA en cours…
CH LES FEUGRAIS CHI ELBEUF
BP 310, 76503 ELBEUF CEDEX
Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).
Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.
Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).
The Lancet. Rheumatology · 2023
The Journal of rheumatology · 2021
Objective.Patient self-report scales are invaluable in psoriatic arthritis (PsA), as they allow physicians to rapidly assess patient perspectives of disease activity. We aimed to assess the agreement of the visual analog scale (VAS), a 100-mm horizontal line, and the numerical rating scale (NRS), a 21-point scale ranging from 0 to 10 in increments of 0.5, in patients with PsA.Methods.Data were collected prospectively across 3 UK hospital trusts from 2018 to 2019. All patients completed the VAS and NRS for pain, arthritis, skin psoriasis (PsO), and global disease activity. A subset completed an identical pack 1 week later. Demographic and clinical data were also collected. Agreement was assessed using medians and the Bland-Altman method. Intraclass correlation coefficients (ICCs) were used to assess test-retest reliability. Spearman rank correlation coefficients were used to assess dependency between scale scores and clinical variables.Results.Two hundred ten patients completed the study; 1 withdrew consent. Thus, 209 were analyzed. For pain, arthritis, skin PsO, and global disease activity, the difference between the VAS and NRS lay mostly within 1.96 SD of the mean, suggesting reasonable agreement between the 2 scales. Among the patients, 64.1% preferred the NRS. The ICCs demonstrated excellent test-retest reliability for both VAS and NRS. Higher VAS and NRS scores were associated with increased tender/swollen joint count, poorer functional status, and greater life impact.Conclusion.The VAS and NRS show reasonable agreement in key patient-reported outcomes in PsA. Results from both scales are correlated with disease severity and life impact.
Rheumatology advances in practice · 2024
Abstract Objective The aim was to assess the use and drug survival of IL-17Ai in a real-world cohort of axial SpA (axSpA) and PsA patients. Methods Patients ever commenced on an IL-17Ai (secukinumab or ixekizumab) for axSpA or PsA at the Leeds Specialist Spondyloarthritis Service were identified. Demographics, IL-17Ai treatment length and reason for cessation were collected. Drug survival data were plotted as a Kaplan–Meier curve, with log rank test of median survival compared between axSpA and PsA. Cox regression analysis was performed to investigate the relationship between diagnosis and length of drug survival. Results In total, 228 patients (91 axSpA and 137 PsA) were exposed to IL-17Ai. Drug survival for all patients at 12 months was 69% (95% Confidence Interval (CI) 63, 75%) and at 24 months 60% (95% CI 54, 67%). In axSpA and PsA, drug survival at 12 months was 63% (CI 54, 74%) and 73% (CI 66, 81%), respectively, and at 24 months it was 53% (CI 44, 65%) and 65% (CI 57, 75%), respectively. Median survival did not differ significantly between both diseases (log rank test 0.65). There was no association between diagnosis and survival (hazard ratio 0.92, 95% CI 0.63, 1.33), including when adjusting for age, previous biologic DMARD usage and sex (hazard ratio 0.89, 95% CI 0.61, 1.13). Conclusion This is the first study, to our knowledge, to analyse and compare real-world IL-17Ai drug survival in patients with axSpA and PsA from a single centre. We demonstrate that there is no difference in IL-17Ai survival rates and no relationship between diagnosis and drug survival. These results contribute to the body of real-world evidence confirming the role of IL-17Ai in the management of axSpA and PsA.
Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).
Rheumatology advances in practice · 2026 · Journal Article
Weddell J, de Boer H, Wong J, Pass B, et al.
Rheumatology (Oxford, England) · 2026 · Journal Article
Meridor K, Harrison SR, Parker R, Chimakurthi R, et al.
Rheumatology (Oxford, England) · 2026 · Journal Article
Meridor K, Harrison SR, Parker R, Chimakurthi C, et al.
Rheumatology (Oxford, England) · 2021 · Journal Article
Vandevelde CY, Harnden K, Freeston J, Barr A, et al.
Rheumatology advances in practice · 2018 · Journal Article
Al Arashi W, Iñiguez Ubiaga C, Hensor EM, Gaffney K, et al.
The Lancet. Rheumatology · 2023 · Journal Article
Md Yusof MY, Arnold J, Saleem B, Vandevelde C, et al.
Rheumatology (Oxford, England) · 2020 · Journal Article
Vandevelde CY, Mandela R, Aaron D, Davis C, et al.
The Journal of rheumatology · 2021 · Journal Article
Ye W, Hackett S, Vandevelde C, Twigg S, et al.
Rheumatology advances in practice · 2022 · Journal Article
Hayward G, Mandela R, Barr A, Freeston J, et al.
Rheumatology advances in practice · 2024 · Journal Article
Weddell J, Din NRA, Harrison SR, Michelena X, et al.